Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2014, 23(4):267-274

Cardial amyloidosis in the context of new pathophysiological knowledge

Poljak Z1, El-Hassoun O2, Hulín I1, Roziaková Ľ1, 3, Janega P4, Mladosievičová B1
1 Oddelenie klinickej patofyziológie LF UK v Bratislave
2 Laboratória patologickej anatómie, Alpha Medical patológia s.r.o. v Martine
3 Klinika hematológie a transfúziológie LF UK a SZU v Bratislave
4 Ústav normálnej a patologickej fyziológie SAV v Bratislave, Slovenská republika

Amyloidosis is a rare but known cause of heart failure, hypertrophic cardiomyopathy, coronary artery damage, disorders of the conduction system and valves. The disease is often unrecognized until an advanced stage. At present, several types of amyloidosis are known. Heart damage usually occurs in AL-amyloidosis. In cases of cardiovascular dysfunction with unclear cause, amyloidosis should be taken into account. In AL-amyloidosis heart damage is the important prognostic factor. In the field of cardiac amyloidosis some interesting pathophysiological knowledge has recently been described. In this minireview we deal with some of it.

Keywords: amyloidosis; cardiotoxicity; transthyretin; cardiac biomarkers

Published: April 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Poljak Z, El-Hassoun O, Hulín I, Roziaková Ľ, Janega P, Mladosievičová B. Cardial amyloidosis in the context of new pathophysiological knowledge. Cardiology Letters. 2014;23(4):267-274.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Guan J, Mishra S, Falk RH, Liao R. Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol. 2012 Feb 1;302(3):H544-552. Go to original source...
    2. Hulín I, Štvrtinová V, Ferenčík M, Kiňová S. Zápal a systémové reakcie. In: Kiňová S, Hulín I, et al. Interná medicína. Bratislava: ProLitera; 2013:22-25.
    3. Kuchynka P, Paleček T, Šimek S, Lubanda JC, Elleder M, Špička I, Jansa P, Linhart A. Izolovaná forma srdeční amyloidózy v podobě počínající infiltrativní kardiomyopatie bez restriktivní fyziologie. Vnitř Lék 2008;54(10):1010-1013.
    4. Gillmore JD, Hawkins PN. Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol. 2013 Oct;9(10):574586. Go to original source...
    5. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31. Go to original source...
    6. Hemminki K, Li X, Försti A, Sundquist J, Sundquist K. Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer. Ann Oncol. 2014 Feb;25(2):511-518. Go to original source...
    7. Sawyer a Skinner. Cardiac amyloidosis: shifting our impressions to hopeful. Curr Heart Fail Rep. 2006 Jun;3(2):64-71. Go to original source...
    8. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation. 2011 Aug 30;124(9):1079-1085. Go to original source...
    9. Elbl L. Měnící se přístup k léčbě AL-amyloidózy - editorial. Vnitř Lék 2013;59(2):96-98.
    10. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003 May 15;101(10):3801-3808. Go to original source...
    11. Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Curr Opin Struct Biol. 2008 Dec;18(6):771-779. Go to original source...
    12. Špalek P. Familiárna amyloidná polyneuropatia. Neurol. prax 2013;14(6):296-300.
    13. Quarta CC, Kruger JL, Falk RH. Cardiac amyloidosis. Circulation. 2012 Sep 18;126(12):e178-e182. Go to original source...
    14. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010 Jan-Feb;52(4):347-361. Go to original source...
    15. Dubrey SW, Falk RH. Amyloid heart disease. Br J Hosp Med (Lond). 2010;71:76-82. Go to original source...
    16. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012 Apr;1(2):e000364. Go to original source...
    17. Steiner I. The prevalence of isolated atrial amyloid. J Pathol. 1987 Dec;153(4):395-398. Go to original source...
    18. Goette A, Röcken C. Atrial amyloidosis and atrial fibrillation: a gender-dependent "arrhythmogenic substrate"? Eur Heart J. 2004 Jul;25(14):1185-1186. Go to original source...
    19. Fikrle M, Paleček T, Kuchynka P, Němeček E, Bauerová L, Straub J, Ryšavá R. Cardiac amyloidosis: A comprehensive review. Cor et Vasa 2013;55:e60-e75. Go to original source...
    20. Millucci L, Ghezzi L, Bernardini G, Braconi D, Tanganelli P, Santucci A. Prevalence of isolated atrial amyloidosis in young patients affected by congestive heart failure. ScientificWorld Journal. 2012;2012:29386 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317626/pdf/TSWJ2012-293863.pdf Go to original source...
    21. Gianni D, Li A, Tesco G, McKay KM, Moore J, Raygor K, Rota M, Gwathmey JK, Dec GW, Aretz T, Leri A, Semigran MJ, Anversa P, Macgillivray TE, Tanzi RE, del Monte F. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation. 2010 Mar 16;121(10):1216-1226. Go to original source...
    22. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, McConnell JP, Burritt MF, Jaffe AS. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003 May 24;361(9371):17871789. Go to original source...
    23. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):19241933. Go to original source...
    24. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum n-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440-2445. Go to original source...
    25. Pika T, Vymětal J, Látalová P. Amyloidóza a postižené srdce. In: Mladosievičová B a kol. Kardioonkologie. Praha: Grada Publishing, a.s.; 2014:186-191.
    26. Palladini G, Merlini G. Systemic amyloidoses: what an internist should know. Eur J Intern Med. 2013 Dec;24(8):729-739. Go to original source...
    27. Peterson FC, Baden EM, Owen BA, Volkman BF, Ramirez-Alvarado M. A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface. Structure. 2010;18:563570. Go to original source...
    28. Martin DJ, Ramirez-Alvarado M. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains. Amyloid. 2010;17:129-136. Go to original source...
    29. Biolo A, Ramamurthy S, Connors LH, O'Hara CJ, Meier-Ewert HK, Soo Hoo PT, Sawyer DB, Seldin DC, Sam F. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail. 2008 Nov;1(4):249-257. Go to original source...
    30. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a noncanonical p38alpha MAPK pathway. Proc Natl Acad Sci USA. 2010;107:4188-4193. Go to original source...
    31. Mishra S, Guan J, Plovie E, Merlini G, Connors LH, Seldin DC, MacRae CA, Liao R. A Novel in vivo Model of Amyloidogenic Light Chain Induced Cardiac Toxicity in Zebrafish. Circulation. 2012;126:A18865. http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A18865 Go to original source...
    32. Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, Gianni D, Jiang B, Del Monte F, Connors LH, Seldin DC, Lavatelli F, Rognoni P, Palladini G, Merlini G, Falk RH, Semigran MJ, Dec GW Jr, Macrae CA, Liao R. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol. 2013 Sep;108(5):378. Go to original source...
    33. Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, Falk RH, MacRae CA, Liao R. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H95-H103. Go to original source...
    34. Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev. 2010 Jan-Feb;18(1):1-11. Go to original source...
    35. Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, Timmons M, Motta A, Phillips SA, Hari P. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2305-H2312. Go to original source...
    36. Halwani O, Delgado DH. Cardiac amyloidosis: an approach to diagnosis and management. Expert Rev Cardiovasc Ther. 2010 Jul;8(7):1007-1013. Go to original source...
    37. García-Pavía P, Tomé-Esteban MT, Rapezzi C. Amyloidosis. Also a heart disease. Rev Esp Cardiol (Engl Ed). 2011 Sep;64(9):797808. Go to original source...
    38. Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, Syed IS, Hughes DA, Lust JA, Jaffe AS, Gertz MA, Klarich KW. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007 Nov 20;116(21):2420-2426. Go to original source...
    39. Feng D, Klarich K, Oh JK. Intracardiac Thrombosis, Embolism and Anticoagulation Therapy in Patients with Cardiac Amyloidosis - Inspiration from a Case Observation. http://cdn.intechopen.com/pdfs-wm/23846.pdf
    40. Dingli D, Utz JP, Gertz MA. Pulmonary hypertension in patients with amyloidosis. Chest. 2001;120:1735-1738. Go to original source...
    41. Miller WL, Wright RS, McGregor CG, et al. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am J Cardiol. 2001;88:813-815. Go to original source...
    42. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989-995. Go to original source...
    43. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovascular Imaging. 2010;3:155-164. Go to original source...
    44. Yusuf SW, Negi SI, Lenihan DJ. Infiltrative cardiomyopathy and pericardial disease. Semin Oncol. 2013 Apr;40(2):199-209. Go to original source...
    45. Ščudla V, Adam Z, Hájek R, Krejčí M, Pika T, Maisnar V, Flodr P, Kufová Z, Látalová P, Potáčová A, Ryšavá R, Špička I, Tichý M, Všianská P. Diagnostika a léčba systémové AL amyloidózy. Transfuze a hematologie dnes 2013;19(Supl.):7-54.
    46. Abbas AK. Diseases of immunity. In: Kumar V, Abbas A.K, Fausto N. Robbins and cotran pathologic basis of disease. 7th edition. Elsevier; 2005:1525. ISBN: 0-7216-0187-1.
    47. Tosoni A, Barbiano di Belgiojoso G, Nebuloni M. Electron microscopy in the diagnosis of amyloidosis. In: Sarantseva S. Amyloidosis - Mechanisms and Prospects for Therapy. 2011;226. ISBN 978-953-307-253-1.
    48. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005 Sep 27;112(13):2047-2060. Go to original source...

    Return to the content